Bayer, Evotec Alliances Create 'Virtual' Specialized Businesses With Finite Goals

 
• By Lucie Ellis-Taitt
  
Generate a summary of this article
Listen to this article
Beta

On the sidelines of the BIO-Europe partnering conference, held in Cologne, Germany, Dr Joerg Moeller, head of development for Bayer's pharmaceuticals division, and Evotec CEO Dr Werner Lanthaler tell Scrip why their partnerships work and what challenges they have overcome to create short-term syndicated businesses with specific therapeutic focuses.

Business man in maze
Bayer, Evotec believe development partnership cuts out inefficiencies and provides clear path to success • Source: Shutterstock

Bayer AG and Evotec AG have recently struck a second collaboration, this time in kidney disease, on the back of their successful discovery and development partnership looking at new drug candidates for women's health indications. Bayer's head of development for pharmaceuticals, Dr Joerg Moeller, and Evotec chief, Dr Werner Lanthaler, told Scrip more about their "modern" setup and how fixed project endings help to eradicate development bottlenecks.

In Oct. 2012 Bayer and Evotec entered into a five-year multi-target strategic alliance to identify three small molecule clinical candidates...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.